2024. Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis. Dermatology Reports. 17, 1 (Aug. 2024). DOI:https://doi.org/10.4081/dr.2024.9999.